News
URGN
--
0.00%
--
UroGen Pharma Ltd. (NASDAQ:URGN): Are Analysts Optimistic?
We feel now is a pretty good time to analyse UroGen Pharma Ltd.'s ( NASDAQ:URGN ) business as it appears the company...
Simply Wall St. · 22h ago
Stifel Nicolaus Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Stifel Nicolaus analyst Derek Archila maintained a Buy rating on Urogen Pharma (URGN) on January 4 and set a price target of $32.00. The company's shares
SmarterAnalyst · 6d ago
Idaho Champion Drills Oxide Gold and Silver Near Historic Pits at Champagne Gold Project
TORONTO, ON / ACCESSWIRE / January 19, 2021 /Idaho Champion Gold Mines Canada Inc. (CSE:ITKO; OTCQB:GLDRF; FSE:1QB1)("IdahoChampion" or the "Company") is pleased to report the results from a 2020 reconnaissance reverse-circulation (RC) drilling campaign at...
ACCESSWIRE · 01/19 12:00
Analysts Are Bullish on These Healthcare Stocks: Urogen Pharma (URGN), Marinus (MRNS)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN), Marinus (MRNS) and Ligand Pharma
SmarterAnalyst · 01/14 11:25
8-K: UroGen Pharma Ltd.
(EDGAR Online via COMTEX) -- false 0001668243 0001668243 2021-01-13 2021-01-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/13 23:06
UroGen Pharma teams up with MD Anderson to advance treatment for bladder cancer
UroGen Pharma (URGN) and The University of Texas MD Anderson Cancer Center announce a strategic three-year collaboration agreement to advance combinatorial intravesical immunotherapy, which is delivered directly into the bladder, for
Seekingalpha · 01/13 13:45
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic t...
Business Wire · 01/13 13:00
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic t...
BusinessWire · 01/13 10:00
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will presen...
Business Wire · 01/06 13:00
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that Liz Barrett, President and Chief Executive Officer, will presen...
BusinessWire · 01/06 10:00
UroGen Pharma's(NASDAQ:URGN) Share Price Is Down 50% Over The Past Three Years.
If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...
Simply Wall St. · 12/18/2020 09:36
Idaho Champion Gold Completes 2020 Exploration Program at Champagne Gold Project
TORONTO, ON / ACCESSWIRE / December 16, 2020 / Idaho Champion Gold Mines Canada Inc.
ACCESSWIRE · 12/16/2020 12:20
The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 15)
Benzinga · 12/16/2020 12:15
Metals & Mining Investor Conference Presentations Now Available for On-Demand Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December Metals & Mining Virtual lnvestor Conference are now available for on-demand viewing.
PR Newswire · 12/11/2020 13:35
Idaho Champion Extends Target at the Baner Gold Project with High Gold in Rock Chips
HIGHLIGHTS * New rock samples from the Baner Trend yield a maximum value of 25.
ACCESSWIRE · 12/07/2020 12:00
Idaho Champion Extends Target at the Baner Gold Project with High Gold in Rock Chips
HIGHLIGHTS * New rock samples from the Baner Trend yield a maximum value of 25.
ACCESSWIRE · 12/07/2020 12:00
Metals & Mining Live Virtual Investor Conference December 8th and 9th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Metals and Mining Virtual lnvestor Conference. Individual investors, institutional investors, advisors, and analysts are invited t...
PR Newswire · 12/04/2020 13:42
Metals & Mining Live Virtual Investor Conference December 8th and 9th
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Metals and Mining Virtual lnvestor Conference. Individual investors, institutional investors, advisors, and analysts are invited to listen to the executive management of metals & mining companies discuss their property positions, development schedules, market opportunity, and investment highlights. The program opens at 8:45 AM ET, with the first webcast at 9:00 AM ET on Tuesday, December 8th.
PR Newswire · 12/04/2020 13:42
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units ("RSUs") to nine ne...
Business Wire · 12/04/2020 13:00
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced the grants of inducement restricted stock units ("RSUs") to nine ne...
BusinessWire · 12/04/2020 10:00
Webull provides a variety of real-time URGN stock news. You can receive the latest news about Urogen Pharma through multiple platforms. This information may help you make smarter investment decisions.
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).